is an albumin preparation manufactured by dilution from the drug product of Albiomin 20% clinical trials

A randomized, placebo-controlled, double-blind, multi-center, phase III trial to assess the efficacy and safety of trimodulin (BT588) in adult hospitalized subjects with CAP including COVID-19 pneumonia.

This study is looking at a new treatment called trimodulin for adults in hospital with pneumonia, including pneumonia caused by COVID-19. Researchers want to see if it makes people better and is safe to use compared to a dummy treatment.